Corrigendum: Development and validation of a m6A -regulated prognostic signature in lung adenocarcinoma

Yaxin Chen, Lei Xia, Yuxuan Peng, Gang Wang, Liyun Bi, Xue Xiao, Li Cui, Weimin LiFrontiers in Oncology 2023 · DOI · OpenAlex

TL;DR

This document is a formal corrigendum (correction) for a previously published study regarding a $m^6A$-regulated prognostic signature in lung adenocarcinoma. It corrects institutional affiliations, updates a broken data repository link for genomic sequences, and clarifies funding sources without altering the original study's scientific conclusions.

What Problem Does This Paper Address?

The original research (published in 2022) addressed the need for better prognostic tools in lung adenocarcinoma (LUAD), the most common subtype of lung cancer. The authors developed a "signature"—a specific pattern of gene expression—regulated by $m^6A$ (N6-methyladenosine), which is a common and influential RNA modification.

This specific corrigendum addresses the "housekeeping" of science: ensuring that the metadata of the research is accurate. Specifically, it fixes errors in:

  1. Institutional Credit: Ensuring the "Institute of Respiratory Health" is properly recognized.
  2. Data Transparency: Fixing a dead link to the raw genomic data, which is vital for reproducibility.
  3. Funding Accountability: Correcting the specific grant numbers that supported the work.

Methods

While the corrigendum itself does not detail the experimental methods, the title and keywords indicate the original study employed epitranscriptomic analysis. This likely involved:

  • Identifying $m^6A$ regulators associated with LUAD.
  • Using bioinformatic pipelines to develop a prognostic signature (a mathematical model used to predict patient outcomes).
  • Validating this signature against clinical data.

The "method" of this corrigendum was a retrospective review of the published metadata to ensure compliance with journal standards and data-sharing requirements.

Datasets

The study relies on the Genome Sequence Archive (GSA) hosted by the BIG Data Center at the Beijing Institute of Genomics.

Key Insights and Ideas

  • The Importance of the "Paper Trail": This correction highlights that scientific publishing is a living record. Errors in funding or affiliation might seem minor, but they affect institutional rankings and grant compliance.
  • Open Science and Reproducibility: By correcting the GSA data link, the authors ensure that other researchers can access the raw data to verify their findings or include them in meta-analyses.
  • Scientific Stability: The authors explicitly state that these administrative errors "do not change the scientific conclusions of the article in any way." This reassures the oncology community that the $m^6A$ prognostic signature remains a valid finding for further clinical investigation.

Key Results

The corrigendum does not provide new quantitative results. According to the original publication (referenced as Front. Oncol. 12:947808), the primary result was the development of a validated $m^6A$-regulated prognostic signature that can help clinicians predict the survival outcomes of patients with lung adenocarcinoma.

Limitations and Future Work

Not discussed in the corrigendum. (The document focuses exclusively on correcting the published record of the 2022 study).

Summary updated

Abstract

[This corrects the article DOI: 10.3389/fonc.2022.947808.].
BibTeX
@inproceedings{chen2023corrigendum,
  author = {Yaxin Chen and Lei Xia and Yuxuan Peng and Gang Wang and Liyun Bi and Xue Xiao and Li Cui and Weimin Li},
  title = {{Corrigendum: Development and validation of a m6A -regulated prognostic signature in lung adenocarcinoma}},
  booktitle = {Frontiers in Oncology},
  year = {2023},
  doi = {10.3389/fonc.2023.1309950},
}

Loading related content...

Figure